Development of an alternative light source to lasers for photodynamic therapy: 1. Comparative in vitro dose response characteristics

1993 ◽  
Vol 8 (4) ◽  
pp. 259-267 ◽  
Author(s):  
C. Whitehurst ◽  
K. Byrne ◽  
J. V. Moore
Keyword(s):  
Photodynamic Therapy ◽  
Light Source ◽  
Dose Response ◽  
Response Characteristics ◽  
Alternative Light Source

Varying dose–response characteristics of different immunoassays and an in-vitro bioassay for FSH are responsible for changing ratios of biologically active to immunologically active FSH

1990 ◽  
Vol 127 (3) ◽  
pp. 523-532 ◽  
Author(s):  
F. Jockenhövel ◽  
S. A. Khan ◽  
E. Nieschlag
Keyword(s):  
Sertoli Cell ◽  
Dose Response ◽  
Serum Levels ◽  
Biologically Active ◽  
Testicular Function ◽  
In Vitro Bioassay ◽  
Great Caution ◽  
Response Characteristics ◽  
Infertile Men

ABSTRACT Serum FSH levels in fertile and infertile men were determined by applying the Sertoli cell in-vitro bioassay and six different immunoassays. Bioassay and immunoassay estimates were significantly correlated (r ranging from 0·78 to 0·86; P<0·01). On average, all immunoassays measured lower FSH concentrations in samples with low FSH levels and higher FSH concentrations in those with high FSH levels compared with the bioassay. Ratios of bioactivity to immunoreactivity (B/I) were highest in fertile men and lowest in men with severe disturbances of testicular function. Depending on which immunoassay was used these differences were either significant or only marginal. Dose–response characteristics for WHO FSH standard preparation 78/549, used in the bioassay as well as in the immunoassays, were different between immunoassays and the bioassay, suggesting that decreasing B/I ratios with increasing FSH serum levels were method-related and reflected different slopes of the dose–response characteristics of the assays, rather than being true changes in the molecular composition of FSH. The present investigation underlines the necessity of choosing the immunoassay used for comparison with the bioassay carefully and of validating the system in regard to parallelism between dose–response characteristics. B/I ratios must be interpreted with great caution and previous studies which report changing B/I ratios in various endocrine situations may have to be reevaluated. Journal of Endocrinology (1990) 127, 523–532

scholarly journals VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites

2018 ◽  
Vol 2 (6) ◽  
pp. 691-702 ◽  
Author(s):  
Katrin J. Czogalla ◽  
Kerstin Liphardt ◽  
Klara Höning ◽  
Veit Hornung ◽  
Arijit Biswas ◽  
...  
Keyword(s):  
Dose Response ◽  
Binding Sites ◽  
In Silico ◽  
Oral Anticoagulant ◽  
Response Characteristics ◽  
Key Points ◽  
Vitro Analysis ◽  
In Vitro Analysis

Key Points VKORC1 is more sensitive than VKORC1L1 to OAC inhibition, whereby 4-hydroxycoumarin rodenticides are equally effective. In silico and in vitro analysis revealed OAC binding sites that are different for VKORC1 and VKORC1L1.

Dose response characteristics of new models of GAFCHROMIC films: Dependence on densitometer light source and radiation energy

2004 ◽  
Vol 31 (9) ◽  
pp. 2501-2508 ◽  
Author(s):  
Sou-Tung Chiu-Tsao ◽  
Tamara Duckworth ◽  
Chuanfang Zhang ◽  
Neil S. Patel ◽  
Chih-Yun Hsiung ◽  
...  
Keyword(s):  
Light Source ◽  
Dose Response ◽  
Radiation Energy ◽  
Response Characteristics ◽  
New Models ◽  
Gafchromic Films

Absence of Synergism Between Tissue-Type Plasminogen Activator (t-PA), Single-Chain UrokinaseType Plasminogen Activator (scu-PA) and Urokinase on Clot Lysis in a Plasma Milieu In Vitro

1986 ◽  
Vol 56 (01) ◽  
pp. 035-039 ◽  
Author(s):  
D Collen ◽  
F De Cock ◽  
E Demarsin ◽  
H R Lijnen ◽  
D C Stump
Keyword(s):  
Human Plasma ◽  
Plasminogen Activator ◽  
Dose Response ◽  
Fibrinolytic System ◽  
Tissue Type ◽  
Clot Lysis ◽  
Single Chain ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator

SummaryA potential synergic effect of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scuPA) or urokinase on clot lysis was investigated in a whole human plasma system in vitro. The system consisted of a human plasma clot labeled with 125I-fibrinogen, immersed in titrated whole human plasma, to which the thrombolytic agents were added. Clot lysis was quantitated by measurement of released 125I, and activation of the fibrinolytic system in the surrounding plasma by measurements of fibrinogen and α2-antiplasmin.t-PA, scu-PA and urokinase induced a dose-dependent and time-dependent clot lysis; 50 percent lysis after 2 h was obtained with 5 nM t-PA, 20 nM scu-PA and 12 nM urokinase. At these concentrations no significant activation of the fibrinolytic system in the plasma was observed with t-PA and scu-PA, whereas urokinase caused significant α2-antiplasmin consumption and concomitant fibrinogen degradation. The shape of the dose-response curves was different; t-PA and urokinase showed a log linear dose-response whereas that of scu-PA was sigmoidal.

Sign in / Sign up

Export Citation Format

Share Document